134 related articles for article (PubMed ID: 25388278)
1. Deformation density components analysis of fullerene-based anti-HIV drugs.
Fakhraee S; Souri M
J Mol Model; 2014 Nov; 20(11):2486. PubMed ID: 25388278
[TBL] [Abstract][Full Text] [Related]
2. Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease.
Yasuno T; Ohe T; Kataoka H; Hashimoto K; Ishikawa Y; Furukawa K; Tateishi Y; Kobayashi T; Takahashi K; Nakamura S; Mashino T
Bioorg Med Chem Lett; 2021 Jan; 31():127675. PubMed ID: 33161121
[TBL] [Abstract][Full Text] [Related]
3. Molecular Dynamics Simulation Study of the HIV-1 Protease Inhibit ion Using Fullerene and New Fullerene Derivatives of Carbon Nanostructures.
Barzegar A; Naghizadeh E; Zakariazadeh M; Azamat J
Mini Rev Med Chem; 2017; 17(7):633-647. PubMed ID: 27292780
[TBL] [Abstract][Full Text] [Related]
4. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
5. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
[TBL] [Abstract][Full Text] [Related]
6. Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase.
Kobayashi T; Yasuno T; Takahashi K; Nakamura S; Mashino T; Ohe T
Bioorg Med Chem Lett; 2021 Oct; 49():128267. PubMed ID: 34271071
[TBL] [Abstract][Full Text] [Related]
7. Modeling interactions between C₆₀ antiviral compounds and HIV protease.
Al Garalleh H; Thamwattana N; Cox BJ; Hill JM
Bull Math Biol; 2015 Jan; 77(1):184-201. PubMed ID: 25583353
[TBL] [Abstract][Full Text] [Related]
8. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins?
Chen YZ; Gu XL; Cao ZW
J Mol Graph Model; 2001; 19(6):560-70. PubMed ID: 11552685
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.
Olomola TO; Klein R; Mautsa N; Sayed Y; Kaye PT
Bioorg Med Chem; 2013 Apr; 21(7):1964-71. PubMed ID: 23415084
[TBL] [Abstract][Full Text] [Related]
10. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
[TBL] [Abstract][Full Text] [Related]
12. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
Zhu Z; Schuster DI; Tuckerman ME
Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
[TBL] [Abstract][Full Text] [Related]
14. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
15. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors.
Ibrahim M; Saleh NA; Hameed AJ; Elshemey WM; Elsayed AA
Spectrochim Acta A Mol Biomol Spectrosc; 2010 Feb; 75(2):702-9. PubMed ID: 20044306
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action.
Freisz S; Bec G; Radi M; Wolff P; Crespan E; Angeli L; Dumas P; Maga G; Botta M; Ennifar E
Angew Chem Int Ed Engl; 2010 Mar; 49(10):1805-8. PubMed ID: 20135654
[No Abstract] [Full Text] [Related]
17. [HIV reproduction inhibition by amino acid and dipeptide derivatives of fullerene C60].
Miller GG; Romanova VS; Pokidysheva LN; Titova IV; Kaliberda EN; Rumsh LD; Andreeva OI; Rybalkin NP
Antibiot Khimioter; 2004; 49(12):3-8. PubMed ID: 16050493
[TBL] [Abstract][Full Text] [Related]
18. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
[No Abstract] [Full Text] [Related]
19. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
Friedman SH; Ganapathi PS; Rubin Y; Kenyon GL
J Med Chem; 1998 Jun; 41(13):2424-9. PubMed ID: 9632374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
